Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Arrhythmias

  Free Subscription


Articles published in J Thromb Thrombolysis

Retrieve available abstracts of 41 articles:
HTML format



Single Articles


    November 2022
  1. LIANOS I, Varlamos C, Benetou DR, Mantis C, et al
    Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention.
    J Thromb Thrombolysis. 2022 Nov 12. pii: 10.1007/s11239-022-02723.
    PubMed     Abstract available


    October 2022
  2. YE TTS, Siah QZ, Tan BYQ, Ho JSY, et al
    Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2022 Oct 3. pii: 10.1007/s11239-022-02713.
    PubMed     Abstract available


    September 2022
  3. SERRAO A, Malfona F, Assanto GM, Orellana MGC, et al
    Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies.
    J Thromb Thrombolysis. 2022 Sep 20. pii: 10.1007/s11239-022-02702.
    PubMed     Abstract available


    June 2022
  4. NOVAK AR, Shakowski C, Trujillo TC, Wright GC, et al
    Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2022 Jun 10. pii: 10.1007/s11239-022-02668.
    PubMed     Abstract available


    May 2022
  5. LIP GYH, Keshishian A, Kang A, Luo X, et al
    Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
    J Thromb Thrombolysis. 2022 May 17. pii: 10.1007/s11239-022-02660.
    PubMed     Abstract available


    April 2022
  6. MARTINEZ KA, Eckman MH, Pappas MA, Rothberg MB, et al
    Prescribing of anticoagulation for atrial fibrillation in primary care.
    J Thromb Thrombolysis. 2022 Apr 21. pii: 10.1007/s11239-022-02655.
    PubMed     Abstract available


  7. DING WY, Rivera-Caravaca JM, Marin F, Roldan V, et al
    Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.
    J Thromb Thrombolysis. 2022 Apr 15. pii: 10.1007/s11239-022-02638.
    PubMed     Abstract available


  8. FROL S, Hudnik LK, Sernec LP, Sabovic M, et al
    Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status.
    J Thromb Thrombolysis. 2022;53:607-615.
    PubMed     Abstract available


  9. DECAMILLO D, Haymart B, Barnes GD
    Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
    J Thromb Thrombolysis. 2022;53:601-606.
    PubMed     Abstract available


    February 2022
  10. POTERE N, Candeloro M, Porreca E, Marinari S, et al
    Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone.
    J Thromb Thrombolysis. 2022;53:346-351.
    PubMed     Abstract available


  11. MEADOR S, Dyke S, Togami J, Kuskov B, et al
    Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics.
    J Thromb Thrombolysis. 2022;53:436-445.
    PubMed     Abstract available


  12. GALLI M, Gargiulo G
    Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment.
    J Thromb Thrombolysis. 2022;53:495-498.
    PubMed    


    January 2022
  13. BAI Y, Liu XY, Liu Y, Guo SD, et al
    Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients.
    J Thromb Thrombolysis. 2022 Jan 24. pii: 10.1007/s11239-021-02622.
    PubMed     Abstract available


    October 2021
  14. LV WH, Dong JZ, Du X, Hu R, et al
    Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
    J Thromb Thrombolysis. 2021 Oct 22. pii: 10.1007/s11239-021-02588.
    PubMed     Abstract available


  15. BEWERSDORF JP, Parmar N, Israel GM, Gettinger SN, et al
    Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.
    J Thromb Thrombolysis. 2021;52:854-862.
    PubMed     Abstract available


  16. CHEN Y, Zhang Y, Qu L, Huang W, et al
    Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure.
    J Thromb Thrombolysis. 2021;52:872-879.
    PubMed     Abstract available


  17. NISLY SA, Mihm AE, Gillette C, Davis KA, et al
    Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:817-827.
    PubMed     Abstract available


  18. SADIQ H, Hoque L, Shi Q, Manning G, et al
    SUPPORT-AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF.
    J Thromb Thrombolysis. 2021;52:808-816.
    PubMed     Abstract available


    September 2021
  19. PAPANASTASIOU A, Kartas A, Samaras A, Vrana E, et al
    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 25. pii: 10.1007/s11239-021-02571.
    PubMed     Abstract available


  20. WANG CL, Wu VC, Tu HT, Huang YT, et al
    Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 23. pii: 10.1007/s11239-021-02570.
    PubMed     Abstract available


  21. OBI CA, Bulsara K, Izard S, Delicce A, et al
    Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall.
    J Thromb Thrombolysis. 2021 Sep 4. pii: 10.1007/s11239-021-02555.
    PubMed     Abstract available


  22. CHEN J, Zhou M, Wang H, Zheng Z, et al
    Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score.
    J Thromb Thrombolysis. 2021 Sep 2. pii: 10.1007/s11239-021-02554.
    PubMed     Abstract available


    August 2021
  23. MENDOZA PA, McIntyre WF, Belley-Cote EP, Wang J, et al
    Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.
    J Thromb Thrombolysis. 2021 Aug 2. pii: 10.1007/s11239-021-02530.
    PubMed     Abstract available


  24. AFZAL S, Zaidi STR, Merchant HA, Babar ZU, et al
    Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting.
    J Thromb Thrombolysis. 2021;52:646-653.
    PubMed     Abstract available


  25. ROMOLI M, Marchetti G, Bernardini F, Urbinati S, et al
    Switching between direct oral anticoagulants: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:560-566.
    PubMed     Abstract available


  26. BASS ME, Kiser TH, Page RL 2nd, McIlvennan CK, et al
    Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus.
    J Thromb Thrombolysis. 2021;52:517-522.
    PubMed     Abstract available


    July 2021
  27. LI RJ, Caughey GE, Shakib S
    Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jul 24. pii: 10.1007/s11239-021-02528.
    PubMed     Abstract available


  28. KAO CC, Wang T, Parulekar AD
    Need for anticoagulation and use of direct oral anticoagulants in lung transplant recipients.
    J Thromb Thrombolysis. 2021;52:232-238.
    PubMed     Abstract available


  29. ROSSIER C, Spoutz P, Schaefer M, Allen A, et al
    Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management.
    J Thromb Thrombolysis. 2021;52:200-208.
    PubMed     Abstract available


  30. WALLVIK N, Renlund H, Sjalander A
    Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants.
    J Thromb Thrombolysis. 2021;52:315-323.
    PubMed     Abstract available


  31. SYLVESTER KW, Wagner C, Lewin A, Fanikos J, et al
    Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience.
    J Thromb Thrombolysis. 2021;52:158-160.
    PubMed    


    June 2021
  32. LU X, Chen T, Liu G, Guo Y, et al
    Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jun 15. pii: 10.1007/s11239-021-02490.
    PubMed     Abstract available


    May 2021
  33. PIAZZA G, Hurwitz S, Goldhaber SZ
    Stroke risk factors and outcomes among hospitalized women with atrial fibrillation.
    J Thromb Thrombolysis. 2021 May 26. pii: 10.1007/s11239-021-02482.
    PubMed     Abstract available


  34. BERNAITIS N, Badrick T, Anoopkumar-Dukie S
    Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
    J Thromb Thrombolysis. 2021 May 7. pii: 10.1007/s11239-021-02466.
    PubMed     Abstract available


  35. GUNER A, Kalcik M, Gunduz S, Gursoy MO, et al
    The relationship between incomplete surgical obliteration of the left atrial appendage and thromboembolic events after mitral valve surgery (from the ISOLATE Registry).
    J Thromb Thrombolysis. 2021;51:1078-1089.
    PubMed     Abstract available


  36. MARCATTO L, Boer B, Sacilotto L, Olivetti N, et al
    Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range.
    J Thromb Thrombolysis. 2021;51:1043-1049.
    PubMed     Abstract available


    April 2021
  37. VINEREANU D, Napalkov D, Bergler-Klein J, Benczur B, et al
    Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    J Thromb Thrombolysis. 2021 Apr 30. pii: 10.1007/s11239-021-02450.
    PubMed     Abstract available


  38. BARTOLAZZI F, Ribeiro ALP, de Sousa WJFN, Vianna MS, et al
    Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study.
    J Thromb Thrombolysis. 2021 Apr 15. pii: 10.1007/s11239-021-02432.
    PubMed     Abstract available


    February 2021
  39. GAVIN O, Grandes J, Garcia MA, Marzo C, et al
    Treatment preferences as basis for decision making in patients using direct oral anticoagulants in Spain.
    J Thromb Thrombolysis. 2021;51:475-484.
    PubMed     Abstract available


    January 2021
  40. NABAVIZADEH P, Steen DL
    Highlights from the European society of cardiology congress 2020.
    J Thromb Thrombolysis. 2021;51:232-236.
    PubMed    


    July 2020
  41. DIEP R, Garcia D
    Should we monitor the direct oral anticoagulants?
    J Thromb Thrombolysis. 2020;50:30-32.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: